Breakdown | ||||
Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
346.82M | 370.43M | 411.24M | 302.06M | 371.63M | Gross Profit |
93.21M | 112.47M | 134.97M | 80.54M | 88.13M | EBIT |
-5.99M | 24.28M | 38.58M | -652.00K | 4.12M | EBITDA |
5.64M | -34.65M | 50.61M | 11.83M | 7.53M | Net Income Common Stockholders |
-19.74M | -55.46M | -10.26M | 2.20M | -16.60M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
41.72M | 50.55M | 62.74M | 74.97M | 75.95M | Total Assets |
479.39M | 477.86M | 508.43M | 580.83M | 538.50M | Total Debt |
41.42M | 40.91M | 44.02M | 84.05M | 80.34M | Net Debt |
4.97M | -9.60M | -9.99M | 9.37M | 5.01M | Total Liabilities |
296.13M | 277.02M | 242.92M | 280.61M | 253.63M | Stockholders Equity |
182.18M | 199.89M | 264.82M | 297.08M | 281.18M |
Cash Flow | Free Cash Flow | |||
-4.94M | -6.07M | 9.25M | -20.00M | -2.44M | Operating Cash Flow |
4.30M | 522.00K | 17.87M | -9.10M | 9.64M | Investing Cash Flow |
-14.13M | 1.76M | -26.00K | 2.90M | -11.68M | Financing Cash Flow |
-4.66M | -2.62M | -23.52M | 33.10M | -6.30M |
Velan Inc. announced the completion of the sale of its French subsidiaries, Segault SAS and Velan S.A.S., to Framatome SAS for a total consideration of $208.4 million. The proceeds from this transaction will be used to fund the permanent divestiture of Velan’s asbestos-related liabilities, enhancing the company’s financial position and potentially impacting its market strategy.
Velan Inc. announced that its shareholders have approved the sale of its French subsidiaries, Segault and Velan S.A.S., to Framatome SAS for a total consideration of US$201.1 million. This transaction is part of Velan’s strategy to use the proceeds to divest its asbestos-related liabilities. The approval was unanimous among voting shareholders, and the transaction is expected to close in the coming weeks, pending customary closing conditions.
Velan Inc. reported strong financial results for its fiscal 2025 third quarter, driven by effective management of a robust order backlog. The company has entered into an agreement to divest its asbestos-related liabilities, enhancing its balance sheet by transferring these liabilities to a new subsidiary and selling its U.S. subsidiary, Velan Valve Corp. Additionally, Velan’s subsidiary, Velan UK, has signed a memorandum of understanding to sell its French subsidiaries to Framatome SAS, a leader in nuclear energy, for $198.4 million. This transaction has been reflected in the company’s balance sheet as assets held for sale, streamlining its operations and focusing on continuing operations.
Velan Inc. announced significant strategic initiatives aimed at reducing operational and financial risks while strengthening its financial standing. The company has agreed to divest its asbestos-related liabilities to Global Risk Capital for $143 million and entered exclusive negotiations with Framatome to sell its French subsidiaries for $175.2 million. These transactions are expected to make Velan nearly debt-free, enabling greater investment in growth opportunities and enhancing shareholder value. Velan remains focused on executing its strategic plan to drive sustained profitable growth and capitalize on the momentum in the clean energy sector.